Dr. Stadler is a clinical trialist focused on developing novel therapies and biomarkers, especially for genitourinary cancer. In addition to an extensive history performing trials in kidney, bladder, and prostate cancer, he also has broad experience in leading efforts supporting clinical trial infrastructure and conduct. These include renal cancer cadre leader for the Cancer and Leukemia Group B (CALGB, now Alliance), PI for a DOD funded prostate cancer clinical trials consortium, co-PI for a Prostate Cancer SPORE, PI for the NCI funded N01 contract for early phase clinical trials, and a current role as Dean for Clinical Research
University of Chicago
Chicago, IL
Postdoctoral Fellow - Oncology
1994
University of Chicago
Chicago, IL
Fellow - Oncology
1993
Michael Reese Hospital
Chicago, IL
Resident - Internal Medicine
1991
Yale University School of Medicine
New Haven, CT
MD - Medicine
1988
University of Illinois
Urbana, IL
BS - Chemistry
1984
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16).
PMID: 37630292
Enrollment Barriers for Molecular Targeted Trials.
Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 Jun 01; 9(6):863-864.
PMID: 37022722
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
PMID: 37182801
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
PMID: 36048457
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec; 20(6):575-580.
PMID: 36210299
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514.
PMID: 35869002
Emerging targets in kidney cancer: opportunities for drug development.
Emerging targets in kidney cancer: opportunities for drug development. Clin Adv Hematol Oncol. 2022 05; 20(5):299-300.
PMID: 35579589
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases.
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627.
PMID: 35034039
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
PMID: 35110415
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
PMID: 35171658